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ACMD 
Advisory Council on the Misuse of Drugs 
Interim Chair: Professor Les Iversen 
Secretary: Will Reynolds 
 
3rd Floor (SW), Seacole Building 
2 Marsham Street 
London  
SW1P 4DF 
 
 
Rt. Hon. Theresa May, MP  
2 Marsham Street 
London  
SW1P 4DF 
 
Rt. Hon. Andrew Lansley, MP 
Department of Health 
Richmond House 
79 Whitehall 
London SW1A 2NS 
 
10th November 2010 
 
Dear Home Secretary and Secretary of State for Health, 
 
The use of foil as a harm reduction intervention 
 
I have pleasure in enclosing the Advisory Council on the Misuse of Drugs’ report 
‘The consideration of the use of foil, as an intervention, to reduce the harms of 
injecting heroin. The provision of foil for the purposes of smoking controlled 
substances, generally heroin and crack cocaine, is illegal under section 9A of the 
Misuse of Drugs Act 1971. The ACMD has been considering the evidence on this 
issue, specifically the position of foil under Section 9A of the Misuse of Drugs Act 
1971. 
 
The Advisory Council on the Misuse of Drugs (ACMD) wrote to your predecessor 
on the 22 October 2009 concerning the ACMD evidence gathering and 
considering the use of foil as a harm reduction intervention.  
 
In the attached report the ACMD has fully considered the available evidence 
regarding the use of foil as a harm reduction intervention. The ACMD considers 
that the balance of benefit favours exempting foil from Section 9A of the Misuse 
of Drugs Act 1971.  
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The evidence of the benefits of the provision of foil, in controlled settings, to 
promote smoking over injecting are several: evidence for a reduction in injecting 
behaviour (with potential for associated reduction in blood borne viruses); greater 
contact between users and treatment services; reduced systemic infections; 
reduced soft tissue and venal damage; lower risk of overdose and reduced litter. 
The dis-benefits of foil provision, in controlled settings, are largely theoretical e.g. 
further individuals being recruited to the user population (by way of foil being a 
route to the use of heroin). The ACMD finds that there is evidence of the benefits 
of foil provision, but can find no evidence of the dis-benefits.      
 
The ACMD would welcome discussing further with you or your officials and being 
part of any on-going discussions.     
 
 
Yours sincerely, 
 
 
 
Professor Les Iversen 
Interim Chair of the Advisory Council on the Misuse of Drugs 
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1. Introduction and Background 
 
1.1. The provision of foil for the purposes of smoking controlled substances, 
generally heroin and crack cocaine, is illegal under section 9A of the Misuse 
of Drugs Act 1971. However, some drug services provide foil to heroin users 
as a cited harm reduction measure. Evidence has been provided to the 
ACMD that some drug intervention agencies supply specialist foil to drug 
users to encourage smoking as a safer alternative to the practice of injecting. 
The foil generally comes with a specified health warning1. 
 
1.2. In most cases foil is provided in packs, in ready cut sheets. It is noted that, 
for the user, kitchen foil is not discreet to carry and is often coated with 
vegetable oil that is generally burned off before use.  
 
1.3. The ACMD began its consideration of the issue of the use of foil as a harm 
reduction measure in July 2008 after a growing body of evidence of its 
potential benefits and also its distribution from drug services.  
 
1.4. Evidence has been presented to the ACMD that the legislation (Section 
9A of the Misuse of Drugs Act 1971) is broadly un-enforced; with respect to 
drug services providing foil in apparent contravention of the Misuse of Drugs 
Act 1971. The ACMD understands that there are various reasons for this: 1) it 
is a low policing priority; rather than expend effort collecting evidence and 
preparing a file for the Crown Prosecution Service (CPS) they would take a 
crime prevention approach and inform those services that were providing foil 
that they should stop; 2) it is reported that some forces are ‘supportive’ of the 
provision of foil as a harm reduction initiative and have, upon request, 
supplied ‘letters of comfort’ which clarifies that they will not produce a report 
to the CPS for prosecution.  
 
1.5. According to the Health Protection Agency (2009), there is some 
uncertainty about the extent of injecting drug use in the United Kingdom. It 
may be as high as 217,000 in England and Wales alone. What is certain is 
that people who inject drugs are especially vulnerable to a wide range of 
infections. These include viruses such as hepatitis C (HCV) and HIV and also 
bacteria such as group A streptococci or Clostridium botulinum.  High rates of 
mortality and illness arise from these infections so public health and 
protective behaviour interventions among injecting drug users (IDU) are 
important. 
 
1.6. In its 2009 report The primary prevention of hepatitis C among injecting 
drug users, the ACMD estimated that: 
 
                                            
1 Details can be found at: 
http://www.exchangesupplies.org/needle_exchange_supplies/foil/foil_intro.html 
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“There are 120,000 to 300,000 (mid estimate 190,000) people that have 
been infected with HCV in England and Wales, and about 50,000 in 
Scotland. 85% became infected through injecting drug use.” 
 
The report concluded that “Ultimately we need to stop injecting to reduce the 
risk of HCV”.  
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2. Background to the evidence underpinning ACMD’s previous 
considerations and recommendations regarding 
paraphernalia [under section 9A of the Misuse of Drugs Act 
1971] 
 
2.1. The ACMD first considered sterile water for injecting (WFI) in 1991 and 
other drug paraphernalia in 1995. The issue was raised again at an ACMD 
meeting in November 1998. Concern had been expressed that drugs workers 
were putting themselves at risk of prosecution when supplying paraphernalia 
in breach of the law.  
 
2.2. A number of reports and studies were discussed at the November 2000 
ACMD Technical Committee meeting: 
 
2.2.1. A report by the Royal Pharmaceutical Society of Great Britain 
(RPSGB) had recommended that section 9A should be amended to 
permit the supply of injecting paraphernalia by pharmacists to drug 
misusers.  
 
2.2.2. A report of the Police Foundation’s Inquiry into the Misuse of Drugs 
Act 1971 (Police Foundation, 2000) had also recommended that 
section 9A should be repealed.  
 
2.2.3. A paper by Sheridan et al. (2000) examined the supply of syringes 
and other injecting equipment by needle exchange schemes in 
South-East England. The researchers collected data from 
approximately 400 community pharmacists and needle exchanges; 
the responses had indicated that 83% of needle exchanges supplied 
swabs and 6% supplied filters.  
 
2.2.4. Research by Crofts et al. (2000) found detectable levels of hepatitis 
C virus on injecting equipment other than needles or syringes – which 
suggested that infection could be transferred to syringes (and 
individuals) through sharing paraphernalia.  The virus had been 
detected on 70% of syringes, 67% of swabs, 40% of filters, 25% of 
spoons and 33% of water samples.  
 
2.3. The ACMD considered a paper on the supply of drugs paraphernalia at its 
meeting in November 2000. The ACMD considered drug paraphernalia and 
WFI at its meeting in May 2001 and subsequently the use of filters in May 
2003.  
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2.4. In May 2001, the ACMD made its recommendation to amend the misuse 
of drugs legislation to permit the supply of swabs, bowls, spoons, stericups, 
citric acid and WFI. In May 2003, the ACMD recommended the inclusion of 
generic filters in the legislation. These recommendations were accepted by 
government.  
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3. Current legal position and background 
 
3.1. Section 9A(1) of the Misuse of Drugs Act 1971, below, makes it an offence 
to supply any article used for administering a controlled drug unlawfully (i.e. 
without a doctor’s prescription). 
  
“A person who supplies or offers to supply any article which may be 
used or adapted to be used (whether by itself or in combination with 
another article or other articles) in the administration by any person 
of a controlled drug to himself or another, believing that the article 
(or the article as adapted) is to be so used in circumstances where 
the administration is unlawful, is guilty of an offence.” 
 
3.2. Section 9A was inserted in the 1971 Act by the Drug Trafficking Act 1986. 
The purpose was to outlaw the supply of cocaine kits (razor blades, foil and 
lemon juice) that were being marketed in the mid-1980s. An exception was 
made for sterile syringes and needles to permit the supply of clean injecting 
equipment to drug users because of their significant harm reducing benefits, 
including reducing the spread of HIV, hepatitis B and hepatitis C and other 
water and blood-borne diseases.  
 
3.3. The ACMD was previously asked to consider whether the supply of 
additional items of paraphernalia should be lawful. (It had become clear that 
some pharmacists and drug workers in needle exchanges were supplying 
such other items contrary to Section 9A in the belief that they were effective in 
reducing the harms associated with injecting drug use). In May 2001, the 
ACMD concluded that certain items had significant harm reducing benefits 
and recommended that the supply of swabs, utensils for the preparation 
(spoons, bowls, cups and dishes), citric acid and ampoules of water for 
injection (when supplied in accordance with the Medicines Act 1968) should 
be lawful, but only if medical practitioners, pharmacists and persons 
employed in the lawful provision of drug treatment services supplied them 
and, from 2005 onwards, a supplementary prescriber. Whilst rejecting them in 
2001, the ACMD subsequently recommended that the supply of filters should 
be lawful in similar circumstances. Cross Government agreement was sought 
by the Home Office and changes were made by secondary legislation – 
Regulation 6A of the 2001 Regulations – in August 2003. (The ACMD 
rejected the inclusion of tourniquets, concluding that the risks outweighed the 
benefits). Following evidence that users injecting crack or freebase cocaine 
tend to use ascorbic rather than citric acid and following the ACMD’s 
recommendation, the 2001 Regulations were further changed in 2005 to 
incorporate ascorbic acid.  
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3.4. In accordance with section 9A, the supply of any other article is prohibited 
where the supplier believes that it will be “used in circumstances where the 
administration [of a controlled drug] is unlawful”, but not otherwise. It is a 
matter for the police and the crown prosecution service respectively to assess 
what policing priority should be given and whether prosecution is in the public 
interest where a drugs worker supplies articles in contravention of section 9A.   
 
3.5. Despite the current legislation 15%2 of UK services have for some time 
contravened section 9A by providing foil. Yet there are no cases of a service 
being charged with an offence (Pizzey and Hunt, 2008). 
 
3.6. The ACMD considers that any advice provided to ministers regarding 
changes in respect of the Misuse of Drugs Act 1971 would need to fulfil two 
criteria:  
 for there to be evidence that the intervention reduced drug related harm; 
and,  
 the intervention would not encourage use of illegal drugs, especially 
heroin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            
2 According to the findings of an online survey conducted by the National Needle Exchange 
Forum (NNEF) between October and November 2008. 
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4. Evidence presented to ACMD regarding the use of foil as a 
harm reduction intervention 
 
4.1. Two key studies provided evidence of how the provision of foil might reduce 
harm among injecting drug misusers in the UK. A published study (Pizzey and 
Hunt, 2008), provided an evaluation of results from an intervention in South 
West England using foil packs to promote a transition away from heroin 
injecting to inhalation. The study analysed data from four needle and syringe 
programmes (NSPs) and interviews with injecting drug users (IDUs) in one 
NSP. A Turning Point report (Boid and Waldock, 2008) described a trial 
scheme entailing the introduction of aluminium foil to Sydney Street needle 
exchange and Sharp Action needle exchange in Sheffield.   
 
4.2. The report by Pizzey and Hunt (2008) showed that foil packs were taken 
when available (out of 320 attendees, 54% took the foil packs). Over the 
period of the evaluation, NSP transactions increased by 32.5% from 1,672 to 
2,216. 
 
4.3. The findings from the Pizzey and Hunt (2008) study suggested that 
distributing foil packs could be a useful means of engaging needle and 
syringe programme (NSP) attendees in discussions about ways of reducing 
injecting risks – thereby reducing harms to users and providing a mechanism 
of engagement to reduce overall use. It could also reduce injecting in settings 
where there was a pre-existing culture of heroin chasing.  
 
4.4. The study called for further research, to evaluate whether the study findings 
(Pizzey and Hunt, 2008) could be reproduced in other cultural contexts and 
evaluate whether the observed behavioural changes were sustained and led 
to reductions in harm including blood-borne infections and overdose.  
 
4.5. The Turning Point report (Boid and Waldock, 2008) details a trial scheme, 
with feedback, where foil was provided at both a site based needle exchange 
(423 packs provided) and an action van (304 packs provided). Whilst the 
feedback received was not analysed it was apparent, from self reported 
results, that the provision of foil reduced injecting behaviour and promoted 
less risky alternatives.  
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4.6. The National Needle Exchange Forum (NNEF) undertook an online 
questionnaire between October and November 2008, the results of which 
were analysed by Liverpool John Moores University. The questionnaire 
produced 445 responses from across the UK, these included responses from 
managers, commissioners, service users and workers. The results of the 
NNEF questionnaire (Chandler et al., 2009) found that 15% of services 
provided foil while 67% of services had no provision due to the current legal 
status. 92% of respondents felt that foil would help reduce harms and 81% 
felt that foil would encourage drug users not to inject. Overall the 
questionnaire indicated that respondents were supportive of foil being 
supplied through needle exchange programmes. The NNEF recommended 
that Aluminium Foil should be added to the current list of exemptions in 
Section 9A of the Misuse of Drugs Act. The NNEF further requested a more 
detailed assessment and review of Section 9A. 
 
4.7. In February 2009 the Association of Chief Police Officers (ACPO) Drugs 
Committee wrote to the ACMD to highlight that ACPO Drugs Committee 
members had been aware that, during the last few years, a number of local 
service providers had taken part in harm reduction initiatives and had 
supplied foil to intravenous drug users in order to encourage a change in their 
consumption habits. The ACPO Drugs Committee cited a scheme operating 
in Somerset Drug and Alcohol Action Team (DAAT) which had received 
prominence following its evaluation in 2008.   
 
4.8. The ACPO Drugs Committee requested clarification of the legislative 
framework provided to all parties involved in these schemes so that local 
health professionals and police do not expose themselves to breaches of the 
law. This is a difficult area since the ACMD is aware that on a local level 
individual forces are providing ‘letters of comfort’, where requested, to needle 
exchanges and services. These letters do not have any legal standing, but 
are a statement that effectively turns a blind eye to the provision of foil by 
services.   
 
4.9. Release provided a submission to the ACMD in March 2009 that supported 
an amendment to section 9A to include foil in the exempted paraphernalia list. 
Release recommended that: 
 There should be an immediate review of section 9A and how it 
impacted on the development of harm reduction initiatives; 
 Consideration to be given to a new system led by medical opinion 
whereby those working in this area could dispense equipment if it 
could be shown to have an effective impact in reducing harm and/or 
acting as a tool for engagement.   
 
 
 12
4.10. A study by Exley (2008) tested the hypothesis that aluminium foil could be 
a significant source of aluminium in users of heroin who were ‘chasing the 
dragon’. These experiments used the same ‘batch’ of street heroin. While 
there was evidence of an increase in bio-available aluminium from heroin 
vaporised off aluminium foil this would not account for the elevated urinary 
excretion of aluminium in heroin users. According to a case study aluminium 
had been found as a contaminant of heroin; e.g. 42 – 2280 µg aluminium g-1 
heroin (Bora et al., 2002). The study also measured the aluminium content of 
‘street’ heroin and found; 48.0  19.6 µg aluminium g-1 heroin (n=9). In 
comparison the aluminium content of tobacco has been found to be; 600-
3700 µg g-1 (Exley et al., 2006) the aluminium content of heroin is generally 
too low to account for the high urinary excretion of aluminium from heroin 
users. 
 
4.11. A presentation on the Dutch experience (Kools, 2009) provided an 
overview of the supply of foil in the Netherlands. The Dutch aim was to 
promote a move away from drug administration by injecting towards less risky 
methods, a practice known as ‘route transition’. It described autonomous 
trends among opiate and stimulant users from injecting towards non-injecting 
drug consumption in the early 1990s. This trend in the drug using community 
was initially recorded in 1992 and became the basis for a range of health 
interventions to promote a shift away from injecting. 
 
4.12. In the Netherlands, the provision of a combination of a full range of health 
interventions (Opiate Substitution Therapy - OST), NSPs, consumption 
rooms, community outreach, peer support, social marketing etc.) led to 
significant individual and public health benefits.  
 
4.13. Currently within the Netherlands foil is available in all needle and  
 syringe exchange programmes (NSEP) and consumption rooms (CR). It was 
highlighted that a success recorded from the intervention had been a 
significant reduction of blood-borne viruses (BBVs) (Kools, 2009). In 
Amsterdam during the last decade “HIV prevalence had fallen from 8.5 per 
cent to virtually zero, and the number of fatal overdoses had also drastically 
decreased” (Kools, 2010). 
 
4.14. The ACMD heard that provision of aluminum foil within NSEPs and CR  
 had not encouraged new users to take up illicit drugs.   
 
4.15. In Scotland, Glasgow Addiction Services have proposed a foil exchange  
 pilot scheme. This followed encouraging results from a recent service user 
evaluation. In October 2009 an anonymous service user questionnaire was 
developed and distributed to service users to evaluate the service and 
establish their views on foil provision. The key findings regarding foil were that 
83% of service users said they would like foil to be offered as part of the 
service and 59% said the provision of foil would encourage them to consider 
smoking rather than injecting.  
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5. Consideration of the evidence 
 
5.1. In all studies the benefits ascribed to the use of foil and the aims of 
providing the foil were multi faceted. They included:  
 To reduce injecting related harms (blood borne viruses, infections, vein 
collapse); 
 To reduce the risks of overdose; 
 To reduce injecting drug use; 
 To engage users to discuss options with a view to reduce harms, 
injecting and ultimately drug use; 
 To reduce drug related litter; and, 
 To reduce drug related crime. 
 
5.2. However, from the present studies it is difficult to specifically quantify the 
reduction in injecting related harms since studies are not constructed to 
measure this. Most of the studies to date have been qualitative in nature and 
have been self-reported.  
 
5.3. In the ACMD’s report on the primary prevention of hepatitis C (ACMD, 
2009) it was noted that there was only weak evidence for the effectiveness of 
many interventions in reducing HCV among IDUs. The key finding was that 
there is emerging epidemiological evidence (supported by preliminary studies 
in the UK) that the combination of opiate substitution therapy (OST) and NSP 
is the most effective way of reducing HCV (and HIV) incidence among active 
IDUs (NSP or OST alone may not be sufficient to prevent HCV). Transposing 
the findings of the ACMD report (2009) it is likely that the provision of foil 
alone, unless a total substitute for injecting behaviour, would not make any 
significant impact on the incidence of blood borne viral infections. 
Nonetheless, foil provision may have an important role within a programme of 
interventions (like other paraphernalia) if it can be used to enforce harm 
reduction messages on the dangers of injection. 
 
5.4. The National Institute for Health and Clinical Excellence (NICE) Public 
Health Guidance 18 Needle and syringe programmes: providing people who 
inject drugs with injecting equipment recognises the importance of NSPs in 
providing a gateway for IDUs to commence OST as a mechanism for 
reducing harm. In this report is was also noted that from fieldwork findings of 
participants who worked at Needle and Syringe Programmes:  
 
‘They were disappointed that the draft guidance did not address the need 
to provide foils and crack pipes to help people who inject to stop.’ 
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5.5. There is evidence from around the world which demonstrates that different 
routes of drug administration are used, and that route transitions3   are a 
common phenomenon. A key example where a successful wide scale change 
of drug ‘route transition’ from injecting to smoking took place was the 
Netherlands. From initial health promotion activities in 1992 about the 
technique of smoking heroin or ‘chasing’ and the provision of aluminum foil, to 
full promotion campaigns to switch to non-injecting a few years later. It seems 
evident that such interventions significantly contributed to a major shift away 
from injecting within the drug using population and the availability of 
aluminum foil seems to have played a significant role in the transition 
process. 
 
‘By the end of the 1990s the development seemed to be complete. Within a 
couple of years an entire generation of drug users in Holland changed their 
rituals and habits and moved away from injecting’4 
 
5.6. The Dutch experience does indicate that the provision of foil can provide a 
platform – when coupled with harm reduction messages and appropriate 
service provision – for the transition from injecting behaviour. Indeed the 
ACMD considers that the evidence from the Netherlands is compelling when 
it comes to making decisions around the provision of foil in the United 
Kingdom. 
 
5.7. The conclusion from the service user evaluation undertaken in Scotland 
(Glasgow Addiction Services, 2010) was that the results supported the 
provision of foil and demonstrated that foil provision could encourage ‘route 
transition’ in injectors. Many of the service users questioned felt that foil 
provision would be both less damaging to people’s health and save money. 
Some also commented on the ability to choose their method of administering 
drugs if given the choice of needles and foil. The anecdotal feedback 
suggested that injecting episodes would be reduced and the chances of 
abstinence increased. 
 
The more services available to people the better chance they will have of 
coming off drugs.’5   
 
5.8. The ACMD considered the use of foil and the risk of bioavailabile6  
aluminium. However, the evidence provided to date does not indicate that the 
levels of aluminium derived from the use of foil constitute a risk to the 
individual. 
                                            
3 A 'route transition' is said to occur when a person changes the method of drug administration 
that they predominantly use. 
4 John Peter Kools, Consultant on Drug Use, HIV and Harm Reduction, Amsterdam, Netherlands 
(2009) 
5 Anonymous respondent, Glasgow Addiction Services, October 2009 Service User 
Questionnaire. 
6 uptake into the body. 
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The ACMD considered the evidence of effectiveness to determine: 
 
Whether there was sufficient evidence (in terms of quantity, quality and 
applicability) to form a judgment:  
The evidence base has not been well developed; borne in part out of the current 
legal restrictions on the provision of foil which means that the intervention has not 
been properly trialled. Further pilot studies are needed to be able to draw firm 
conclusions. However, the available evidence, the ACMD believe, is sufficient to 
enable an informed judgment. The evidence suggests that the introduction of foil 
would bring positive benefits. Foremost of these is the greater contact between 
users and treatment services. This allows for greater impact to be made on user 
behaviours and increases the opportunity to provide public health messages.       
 
Whether, on balance, the evidence demonstrates that the intervention is 
effective or ineffective, or whether it is equivocal:    
As outlined above (Section 5) there is evidence of actual and potential benefits. 
However, what is more difficult to elucidate, from the presently available 
evidence, are any potential dis-benefits - such as further individuals being 
recruited to the using population (by way of foil being a route to the use of 
heroin).  The results from the Amsterdam Cohort Study 1986-1998 (van 
Ameijden and Coutinho, 2001) which followed nearly a thousand drug users, 
showed that injecting initiation linearly decreased (4.1% to 0.7% per visit) 
following the introduction of harm reduction policies which included the provision 
of foil. The study concluded that a harm reduction approach did not lead to an 
increase in injecting drug use.  
 
Where there is an effect, the typical size of effect:   
Although the evidence is limited, what is available suggests an impact could be 
made on user behaviour. The Pizzey and Hunt study (2008) showed a take up 
rate of more than half of service users. The Glasgow survey results appear to 
support that figure. In Amsterdam HIV prevalence had been reduced to almost 
zero. 
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6. Conclusion and Recommendations 
6.1. Having considered the evidence regarding the provision of foil as exempt 
under the Misuse of Drugs Act 1971, the ACMD concluded that there were 
three possible options as follows: 
 
1. No change to current legal status 
2. Implementation of a pilot scheme for foil provision 
3. Recommendation that foil be exempted under Section 9A of the Misuse 
of Drugs Act 1971 
 
6.2. The ACMD considers that on the current balance of evidence foil is 
exempted under Section 9A of the Misuse of Drugs Act 1971. The ACMD 
concludes that there is: 
 
a) No evidence of harmful effect of the provision of foil. 
 Previous studies have indicated that the intervention does not 
encourage the use of illegal drugs 
 
  b) The potential benefits include:  
 Potential for a decrease in blood borne viruses;  
 Increased contact and engagement with drug service workers; 
 Reduced systemic infections; 
 Reduced soft tissue and venal damage; 
 Lower risk of overdose; and, 
 Reduced litter. 
 
The ACMD would note that the recommendation of foil is different from that on 
other paraphernalia as it is not directly associated with injecting practice. Rather, 
the use of foil is specifically designed to move individuals away from injecting 
practice and the associated high risks of blood borne viruses and overdose. In 
this context the standard of evidence of proof, for the exemption of foil from 
Section 9A of the Misuse of Drugs Act 1971, may therefore be intuitively higher 
than for other paraphernalia. However, the ACMD believes that this report 
demonstrates a weight of evidence in favour of exempting foil as a harm 
reduction intervention7.  
 
 
 
 
 
                                            
7 The ACMD noted the findings of the National Institute for health and Clinical Excellence (NICE) 
evaluation on NSP overall that while there were sizeable gaps in the evidence base for 
effectiveness they could support the continued or extended provision. This reflected the positive 
balance of probabilities approach. 
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